基质金属蛋白酶MMP-2及MMP-9在淋巴系肿瘤中的表达

Expression of MMP-2 and MMP-9 in Malignancies of Systema Lymphaticum

目的探讨基质金属蛋白酶ProMMP-2、MMP-2、ProMMP-9和MMP-9与淋巴系肿瘤的相关性。方法应用明胶酶谱(SDS-PAGE Zymograph)和计算机蛋白定量测定系统,对62名淋巴系肿瘤患者(初发组35名,复发组12名,缓解组15名)和20名正常人,测定其血清中ProMMP-2、MMP-2、ProMMP-9和MMP-9的表达水平。结果初发组、复发组患者血清中ProMMP-2、MMP-2和MMP-9的表达水平明显高于缓解组和对照组。而初发组、复发组患者血清中ProMMP-9表达水平与缓解组和对照组差异无显著意义;初发组患者血清中ProMMP-2、MMP-2、ProMMP-9和MMP-9表达水平与复发组相比差异无显著意义。缓解组患者血清中ProMMP-2、MMP-2、ProMMP-9和MMP-9表达水平与对照组差异无显著意义。结论MMP-2和MMP-9与淋巴组织恶性肿瘤发生及发展呈正相关;ProMMP-2、MMP-2和MMP-9可作为判断病情及评价治疗效果的指标;为进一步研制相关MMP抑制剂及为淋巴组织肿瘤治疗提供新的靶向位点奠定了基础。

Objective To explore the relationship between metal matrixpretease （MMP） and the malignancies of systema lymphaticum. Methods Determine the expression of ProMMP-2, MMP-2, ProMMP-9 and MMP-9 in sere of 62 patients with malignancies of systema lymphatienm （35 at primary onsetstage, 12 at recurrence stage and 15 at remission stage） by SDS-PAGE zymograph and computer protein quantitative determination system, using those in 20 healthy persons as control. Results The expression levels of MMP-2, MMP-2 and MMP-9 in the sera of patients at primary onset and recurrence stages were significantly higher than those in control group. The expressions of ProMMP-2,MMP-2,ProMMP-9 and MMP-9 in sere of patients at remission stage showed no significant difference with those in control group. However, the expression levels of ProMMP-9 in the sere of patients at primary onset and recurrence stages showed no significant difference with those in the patients at remission stage and in control group. The expression levels of ProMMP-2, MMP-2, ProMMP-9 and MMP-9 in sere of patients at primary onset stage showed no significant difference with those at recurrence stage. Conclusion The expression levels of MMP-2 and MMP-9 were positively related to the onset and progress of malignancies of systema lymphaticurn. ProMMP-2, MMP-2 and MMP-9 mignt be used as the indexes for the judgment of disease course and evaluation of curative effect. It laid a foundation of further development of relevant MMP inhibitor for the treatment of malignancies of systema lymphaticum.